Gritstone Bio Long Term Debt 2017-2024 | GRTSQ
Gritstone Bio long term debt from 2017 to 2024. Long term debt can be defined as the sum of all long term debt fields.
Gritstone Bio Annual Long Term Debt
(Millions of US $) |
| 2023 |
$40 |
| 2022 |
$19 |
| 2021 |
$ |
| 2020 |
$ |
| 2019 |
$ |
| 2018 |
$10 |
| 2017 |
$11 |
| 2016 |
$ |
Gritstone Bio Quarterly Long Term Debt
(Millions of US $) |
| 2024-06-30 |
$41 |
| 2024-03-31 |
$40 |
| 2023-12-31 |
$40 |
| 2023-09-30 |
$30 |
| 2023-06-30 |
$30 |
| 2023-03-31 |
$30 |
| 2022-12-31 |
$19 |
| 2022-09-30 |
$19 |
| 2022-06-30 |
|
| 2022-03-31 |
|
| 2021-12-31 |
|
| 2021-09-30 |
|
| 2021-06-30 |
|
| 2021-03-31 |
|
| 2020-12-31 |
|
| 2020-09-30 |
$21 |
| 2020-06-30 |
|
| 2020-03-31 |
|
| 2019-12-31 |
|
| 2019-09-30 |
|
| 2019-06-30 |
|
| 2019-03-31 |
|
| 2018-12-31 |
$10 |
| 2018-09-30 |
$11 |
| 2018-06-30 |
|
| 2018-03-31 |
|
| 2017-12-31 |
|
| 2017-09-30 |
|
| 2016-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.000B |
$0.016B |
|
Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight multiple cancer types. The company has built its tumor-specific immunotherapy approach on two key pillars - first, a proprietary machine learning-based platform, Gritstone EDGE(TM), which provides a powerful ability to predict from a routine tumor biopsy the tumor-specific neoantigens, or TSNA, that are presented on a patient?s tumor cells; and second, the ability to develop and manufacture potent immunotherapies utilizing patients? TSNA to drive the patient?s immune system to attack and destroy tumors.
|
